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Secreted amyloid precursor protein alpha (sAPPα) is produced by α-secretase cleavage of 
amyloid precursor protein (APP). Not only is sAPPα of interest because its production 
competes with amyloid beta (Aβ) production which is involved in Alzheimer’s disease (AD), 
but it is also neuroprotective and neurotrophic. Due to these positive effects on the brain, it 
has been suggested as a potential therapeutic agent for AD treatment. Past studies have 
shown sAPPα to increase protein synthesis, which is thought to be one of the underlying 
mechanisms of its beneficial effects, but its course of action is still not fully understood. 
Group 1 mGluRs also have been found to increase protein synthesis. Due to the action of 
both sAPPα and Group 1 mGluRs converging at this point, it raises the question of whether 
they are acting together or separately. Two amino acid sequences within sAPPα; RER 
(peptide in the E2 region) and CTα16 (peptide chain that differentiates sAPPα from sAPPβ, 
which is the precursor of Aβ) have also shown promise in being used as a therapeutic agent. 
Smaller peptides are usually preferred over larger proteins in therapeutic agents and therefore 
they are of great interest. The aim of this thesis was to investigate a possible interaction 
between Group 1 mGluRs and α-secretase and to test the effects both RER and CTα16 have 
on protein synthesis. Exogenous sAPPα and several agonists/antagonists were applied (30 
minutes) in vitro to investigate protein synthesis in CA1 hippocampal mini-slices from 6-8-
week-old male Sprague Dawley rats. The surface sensing of translation (SUnSET) technique 
was used to measure changes in global protein synthesis across groups.  
Application of sAPPα (10 nM) and Group 1 mGluR agonist (S)-3,5-
dihydroxyphenylglycine (DHPG, 20 μM) both significantly increased protein synthesis. 
Furthermore, α-secretase antagonist TAPI-1 (20 μM) inhibited the increase caused by DHPG 
while the Group 1 mGluR antagonist LY341495 (100 μM) did not inhibit the increase caused 
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by exogenous sAPPα. These results indicate that Group 1 mGluRs were working upstream of 
α-secretase in a serial pathway to produce an increase in protein synthesis.  
Application of RER at both 1 nM and 10 nM concentrations significantly increased 
protein synthesis in a similar manner to full length sAPPα. Using a modified sAPPα chain in 
which the RER site was replaced with three alanine (1 nM), the increase was inhibited. 
Similarly, CTα16 at both 1 nM and 10 nM concentrations significantly increased protein 
synthesis in a sAPPα like manner. A scrambled variant of sAPPα (10 nM) showed no 
significant increase compared to control. These results show support for RER and CTα16 
being not only required but sufficient to mimic sAPPα in increasing protein synthesis.  
Overall, the present study shows support for a novel serial pathway of action between 
sAPPα and Group 1 mGluRs as well as evidence for two functional domains of sAPPα being 
able to increase protein synthesis. These findings have implications for understanding the 
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Investigating Secreted Amyloid Precursor Protein-alpha and its Functional Domains in 
Stimulating Hippocampal Protein Synthesis 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder 
worldwide and currently there is no cure. The formation and deposition of amyloid-beta (Aβ) 
from cleavage of amyloid precursor protein (APP) is one of the major neuropathological 
hallmarks of AD (Selkoe, 2001). Because it is a chronic disease, any potential treatments 
must be not only effective, but long lasting. One of the proposed treatments for AD is the use 
of secreted amyloid precursor protein-alpha (sAPPα). sAPPα has been found to be 
neuroprotective, neurotropic and neurogenic, but currently the mechanisms of action for 
sAPPα are not well understood (Mockett et al., 2017). This research will focus on sAPPα and 
its ability to increase de novo protein synthesis. A potential relationship between sAPPα and 
Group I metabotropic glutamate receptors (mGluRs) will be investigated as well as two 
peptides of interest in the form of RER (amino acid sequence at a proposed active site of 
sAPPα) and CTα16 (peptide chain that differentiates sAPPα from sAPPβ, which is the 
precursor of Aβ).  
Amyloid Precursor Protein 
APP is an integral membrane protein that is expressed throughout the brain especially 
at neuronal synapses. It belongs to a family of conserved type I membrane proteins (Martin-
Morris & White, 1990). There are three mammalian APP homologs, namely APP, APP-like 
protein 1 (APLP1), and APP-like protein 2 (APLP2). APLP1 expression is only found in 
neurons whereas APP and APLP2 are expressed both in and outside the brain (Martin-Morris 
& White, 1990). In humans, the APP gene is located on chromosome 21 and contains 18 
exons (Yoshikai et al., 1990).  
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The process of APP synthesis is modulated through a constitutive secretary pathway  
and is post-translationally modified by N- and O-glycosylation, phosphorylation, and tyrosine 
sulfation (De Strooper & Annaert, 2000). At full length, APP is cleaved by three proteases; 
α-, β-, and γ-secretases. Cleavage by either α- or β-secretase results in release of most of the 
ectodomain, i.e., soluble APP derivatives known as secreted APPα (sAPPα) and secreted 
APPβ (sAPPβ) and membrane-tethered α- or β-carboxyl-terminal fragments (APP-CTFα and 
APP-CTFβ). These carboxyl-terminal groups are further cleaved by γ -secretase to generate 
p3 from APP-CTF α or Aβ from APP-CTF β and the APP intracellular domain (AICD) (De 
Strooper & Annaert, 2000).  
 
 
Figure 1. Basic structure and proteolysis model for APP. EC-extracellular & IC-intracellular. 
(Zheng & Koo, 2011, p. 3). 
The most common neuronal β-secretase is BACE1 (beta-site APP cleaving enzyme). 
BACE1 is a transmembrane aspartyl protease which generates the N-terminus of Aβ. It is 
also important for the formation of myelin sheath around nerve cells in the peripheral nervous 
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system (Vassar et al., 1999). It has two active sites in its extracellular domain and is thought 
to function as a dimer.  
For cleavage at the α-site, it was originally believed that members of the ADAM (a 
disintegrin and metalloprotease) family of proteases including ADAM9, ADAM10 and 
ADAM17 were acting as α-secretase. Studies have shown that, ADAM10 is the main 
mediator for α-secretase activity (Kuhn et al., 2010; Lichtenthaler, 2011). Following this, it 
was found that transcription of ADAM10 was regulated by sirtuins (Bonda et al., 2011). 
Sirtuins are a class of proteins that regulate important biological pathways. It has been shown 
that SIRT1 supresses Aβ production and therefore activation of α-secretase competes with the 
activation of β-secretase (Endres & Fahrenholz, 2012).  
A further enzyme of interest is γ-secretase. Its activity resides in presenilin and is an 
aspartyl protease (Wolfe et al., 1999). The mature γ-secretase complex involves a few other 
proteins including nicastrin, anterior pharynx defective and presenilin enhancer (Edbauer et 
al., 2003). As mentioned before, γ -secretase cleavage of APP results in the formation of Aβ 
peptides. Yagishita et al. (2006), showed in a series of studies that this is done by cleaving 
APP in multiple sequential steps. They created a model that showed sequential cleavage 
taking place every three residues along the α-helical face of the transmembrane domain of 
APP which in turn shortens the C-terminus and results in the release of Aβ. 
The aforementioned secretases do not have unique specificity towards APP. BACE1 
has a low affinity for APP which suggests that APP is not its only physiological substrate. 
Other transmembrane proteins such as growth factors, cytokines and cell surface receptors 
have been found to undergo ectodomain shedding by enzymes with α-secretase activity 
(Tousseyn et al., 2009). γ -secretase has also been reported to cleave more than 50 other type 
I membrane proteins (Wolfe & Kopan, 2004). Like APP, γ-secretase activity on other 
transmembrane proteins often is preceded by α-secretase activity (Wolfe & Kopan, 2004). 
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The extracellular sequence of APP can be divided into domains based on primary 
sequences. The E1 domain is made up of the N-terminal growth factor-like domain (GFLD) 
and the metal binding motif. The crystal structure of the E1 domain resembles already known 
cysteine-rich growth factors and therefore the N-terminus of APP has been linked to GFLD. 
The E2 domain includes a five amino acid sequence reported to possess neurotrophic 
functions (RERMS), and the extracellular matrix components (Reinhard et al., 2005). Most 
studies have suggested that the role of the extracellular domain of APP is related to its 
synaptotrophic and neuroprotective function. One of the first studies to show a potential role 
of APP blocked APP production in fibroblasts with antisense APP (Saitoh et al., 1989). 
Results showed, that fibroblasts treated with antisense APP grew slower and that this 
retardation in growth could be restored by treating them with sAPPα. APP expression has 
been shown to be upregulated during neuronal maturation and differentiation (Bibel et al., 
2004). During traumatic brain injury in both mammalian systems and in Drosophila, APP 
expression was increased (Leyssen et al., 2005). This indicates that APP could play a role in 
the recovery process of brain injury.  
The intracellular sequence is highly conserved throughout the APP isoforms which 
could suggest that it is important for the mediating its function. The domain itself is only 47 
amino acids in length and contains a phosphorylation site, multiple functional motifs and 
multiple binding partners (Suzuki & Nakaya, 2008). APP can be phosphorylated at many 
sites both in the intracellular and extracellular domain but the threonine residue within the 
VT668PEER motif in the intracellular section has been extensively studied. Phosphorylation at 
this residue has been reported to have several outcomes. The most common function 
proposed is that it regulates APP localization to neurites (Muresan & Muresan, 2005). 
Phosphorylation at Thr668 has also been reported to contribute to Aβ generation which is 
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supported by a study that showed an increase in Thr668 phosphorylated APP fragments in AD 
patients (Lee et al., 2003).   
The role of APP has been thoroughly studied ever since its cDNA was cloned. It was 
subsequently proposed to be a cell surface receptor. Hence, the proteolytic processing profiles 
of APP were very similar to that of the Notch receptor, a known cell surface receptor (Selkoe 
& Kopan, 2003). In order to support this hypothesis, multiple studies were conducted to give 
APP the properties of a cell surface receptor. Firstly, it was found that Aβ could bind to APP 
and thus could be a ligand for APP (Lorenzo et al., 2000). This finding was supported and 
replicated by another study (Lu et al., 2003). More recent studies have shown that multiple 
proteins have also been shown to interact with the APP ectodomain. It was found that the 
extracellular domain of APP binds to F-spondin which is a neuronally secreted glycoprotein. 
The role of this was to regulate Aβ production and mediate downstream signalling pathways 
(Ho & Südhof, 2004). Another example is the Nogo-66 receptor which is thought to also 
affect Aβ production (Park et al., 2006). Finally, Netrin-1, a soluble molecule that plays a 
role in axonal guidance through chemoattraction was found to interact with APP (Lourenco et 
al., 2009). Although the number of potential ligands for APP is extensive, there remains no 
definitive evidence showing that APP functioning solely as a cell surface receptor.  
Another potential role of APP was proposed to be cell and synaptic adhesion. The E1 
and E2 regions of the extracellular domain have been shown to interact with both matrix 
proteins and heparin sulfate proteoglycans (Small et al., 1999).  Heparin binding to the E1 or 
E2 region was shown to induce the formation of APP dimerization (Dahms et al., 2010). To 
test this further, X-ray analysis was performed, and the results showed that the E2 domain 
could form either parallel or antiparallel dimers. The significance of antiparallel dimers is that 
they show a potential function in trans-cellular adhesion (Wang & Ha, 2004). Cell culture 
studies also support the homo- or hetero- dimer formation of APP with trans-dimerization 
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shown to promote cell-cell adhesion. This study supported the idea that APP may play a role 
in cell-substratum or cell-cell adhesion. The most compelling findings came in a mixed 
culture assay. It contained neuron/HEK293 and in this culture system, trans-cellular 
APP/APP interaction induced presynaptic specializations in co-culture neurons (Wang et al., 
2009). This suggested that APP proteins were acting as synaptic adhesion molecules. Once 
again, although there is evidence for a potential function of APP, the exact way APP 
influences or mediates cell adhesion is not well understood.  
sAPPα 
Although the difference between sAPPβ and sAPPα is only 16 amino acids, there are 
dramatic differences in how they act in the brain. There is extensive of evidence to show the 
beneficial roles of sAPPα but evidence for the role of sAPPβ seem to point towards it being 
harmful. Nikolaev et al. (2009) for example, showed that under trophic withdrawal conditions 
only sAPPβ undergoes further cleavage to produce an N-terminal derivative (N-APP) which 
binds to DR6 death receptor and regulates axon pruning and degeneration. This finding 
suggested that further processing of sAPPβ leads to neurodegeneration in both normal aging 
and AD.  
The role of sAPPβ seemed to be modulating downstream proteins such as 
transthyretin and enzymes such as Klotho (Li et al., 2010). These two targets are known to 
play a role in AD. Transthyretin is known to bind Aβ and Klotho is vital in aging by 
controlling sensitivity to insulin (Kuro-o et al., 1997). The fact that sAPPβ regulates these 
two molecules of interest supports the idea that there is a self-protective mechanism in the 
APP processing pathway. More specifically, it means that the pathway counters the 
production and toxicity of Aβ during aging. It has been found that secreted APP levels are 
much lower in AD patients and this could give more evidence to support that the 
SECRETED APP ALPHA AND PROTEIN SYNTHESIS 
7 
 
neurodegeneration seen in AD is at least partly due to the lack of sAPPα (O’Brien & Wong, 
2011; Long et al., 2019).  
sAPPα has been found to have many beneficial effects in the brain. More specific 
studies looking at sAPPα in vivo demonstrated that sAPPα can mediate synaptic plasticity 
and spatial memory (Taylor et al., 2008). In earlier studies, it was found that when sAPPα 
was infused into the brain of adult rats, they had increased synaptic density and better 
memory retention (Meziane et al., 1998). Higher levels of sAPPα in the brain showed an 
improvement in neurogenesis (Roch et al., 1994). Application of sAPPα following traumatic 
brain injury also produced an improvement in functional recovery (Thornton et al., 2006). 
Finally, it was shown that sAPPα reduced dendritic degeneration and neuronal death 
following proteasomal stress (Copanaki et al., 2010).  
Mentioned above is that sAPPα may be enhancing synaptic plasticity. Synaptic 
plasticity is defined as a lasting upregulation or downregulation of synaptic strength that can 
be either NMDA (N-methyl-D-aspartate) receptor dependent or independent (Martin & 
Morris 2002). NMDA receptors are ionotropic glutamate receptors which when activated 
allow calcium (Ca2+) ions to flow into the cell (Furukawa et al., 2005). Plasticity can increase 
or decrease the efficacy of synaptic transmission through either long-term potentiation (LTP) 
or long-term depression (LTD), respectively. 
Many studies have shown that sAPPα can facilitate LTP. Ring et al. (2007) showed 
that sAPPα can rescue impaired LTP of APP-deficient mice. This was followed by a more 
recent study where conditional APP/APLP2 double KO mice were created to test the effects 
of adding recombinant sAPPα and sAPPβ (Hick et al., 2015). The knockout mice, which 
were lacking any sAPPα due to the mutation, showed impairments in hippocampal LTP and 
behavioural activities related to hippocampal memory. After acute administration of 
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recombinant sAPPα, the LTP was restored. This effect was not seen when sAPPβ was added 
(Hick et al., 2015). 
To fully understand what role sAPPα is playing in LTP, it is important to break down 
the mechanisms of plasticity. Although the exact proteins are unknown, the consensus is that 
protein synthesis is required for LTP to be maintained (Ryan et al., 2015; Tsokas et al., 2016; 
Bliss et al., 2018). This has been supported by studies that show that addition of protein 
synthesis inhibitors affects the persistence of LTP (Abraham & Williams, 2003). The role of 
the newly synthesised proteins may be to help make the new synaptic changes more 
permanent and to aid in the activity-dependent structural changes. Two transcription factors 
thought to be important post LTP induction are CREB and zif/268. These two factors are 
thought to be important in the transcription dependent phase of LTP with knock-down in both 
factors shown to cause impairment in LTP and long-term memory (Jones et al., 2001). After 
LTP induction, the two main CREB-responsive genes formed are activity related cytoskeletal 
protein (Arc) and PKMzeta (Lyford et al., 1995). The role of Arc is to move its mRNA to 
dendrites where activity dependent translation occurs. Knock-down of Arc has been shown to 
impair LTP maintenance. Similarly, application of PKMzeta inhibitor also impairs LTP 
maintenance (Serrano et al., 2005). Therefore, these two examples support the proposal of 
LTP maintenance being protein synthesis dependent.  
However, some studies have also shown that protein synthesis may not be required for 
LTP. One study showed that the application of mature brain-derived neurotrophic factor 
(BDNF) in the presence of the protein synthesis inhibitor anisomycin helped stabilize in vivo 
LTP (Pang et al., 2004). This result suggested that in the presence of BDNF, LTP may be 
protein synthesis independent. A further study reported that LTP could be maintained for 
hours during protein synthesis inhibition if proteasome degradation of proteins was also 
inhibited (Fonseca et al., 2006). A common hypothesis following these studies was that 
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protein synthesis in LTP was only to replenish the proteins that were used up in the enhanced 
synaptic activity. Follow up studies showed that late-phase of LTP was not impaired by 
anisomycin if no test pulse was delivered during the time of measurement (Fonseca et al., 
2006). However, in late-phase, LTP was impaired if a test pulse was delivered. This 
suggested that protein synthesis was not required for the maintenance of LTP, but synaptic 
activity during maintenance depleted proteins necessary for LTP. Although it may look like 
these studies show that maintenance of LTP is protein synthesis independent, it is more than 
likely that late-phase LTP can be artificially shown to be unaffected by the presence of no 
new protein synthesis.  
One of the proposed mechanisms by which sAPPα enhances LTP is via protein 
synthesis. Because protein synthesis plays a significant role in the maintenance of LTP, if 
sAPPα was activating it, reflections could be seen in LTP. In LTP experiments, the term 
priming means previous exposure to electrical stimulation in which the stimulation causes a 
difference in the result. Hippocampal slices from adult rats were put under short-term 
potentiation or long-term depression protocols and their electrophysiological recordings were 
measured (Mockett et al., 2017). Mild stimulation resulted in short-term potentiation without 
LTP but with bath application of sAPPα (priming) 30 minutes prior to stimulation, LTP was 
induced. This sAPPα induced increase in potentiation was not present when the protein 
synthesis inhibitor cycloheximide was added. Bath application of sAPPα had no effect on 
LTD induction. These experiments showed that sAPPα may be priming synapses for later 
LTP expression and aids in the maintenance of LTP by enhancing protein synthesis (Mockett 
et al., 2017).  
Claasen et al. (2009), investigated the effect of sAPPα on protein synthesis in rat 
hippocampal synaptoneurosomes. Exogenous sAPPα was applied and protein synthesis 
measured using the incorporation of [35S]-methionine. They found that exogenous sAPPα 
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(10nM) increased the rate of incorporation of [35S]-methionine into acid-precipitated 
proteins within the synaptoneurosomes. This finding implied that sAPPα was increasing the 
rate of de novo protein synthesis. When the protein kinase G specific inhibitor KT5823 was 
added, the increase caused by sAPPα was completely blocked. The use of KN62 (CaMKII 
inhibitor) and PD98059 (p24-44 MAPK inhibitor) reduced but did not fully eliminate the 
increase caused by sAPPα. As expected, exogenous sAPPβ (10 nM) caused no increase in 
protein synthesis. This study showed that sAPPα may be working in a protein synthesis 
dependent manner to achieve the enhancement seen in LTP experiments.  
Metabotropic Glutamate Receptors  
Metabotropic glutamate receptors (mGluR) are a subtype of glutamate receptors that, 
unlike ionotropic receptors, act through a second messenger through a signalling cascade 
initiated by ligand binding. This biochemical cascade can regulate downstream proteins or 
ion channels and can modify the synapse’s excitability, i.e. neurotransmission (Sladeczek et 
al., 1993). In the case of mGluRs, they are in the type C of G-protein coupled receptors 
(GCPRs). There are eight different types of mGluRs divided into three different groups. They 
have a wide range of functions from learning and memory to anxiety and pain (Ohashi et al., 
2002) and often work by regulating the activity of other receptors. Examples of modulation 
include group I mGluRs which are known to increase NMDAR activity (Skeberdis et al., 
2001).  
The focus of this research will be on group I mGluRs. Activation of these receptors 
causes the enzyme phospholipase C to hydrolyze phospholipids in the cell’s plasma 
membrane (Bonsi et al., 2005). Furthermore, this causes the formation of diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3). Here, the two molecules perform two distinct 
actions: DAG is lipophilic and therefore stays within the membrane and acts as a co-factor 
for the activation of protein kinase C (Chu & Hablitz, 2000), while IP3, being hydrophilic, 
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travels out of the membrane to the endoplasmic reticulum where it opens calcium channels to 
increase the cytosolic calcium concentration. Unlike group II and group III mGluRs, group I 
mGluRs are found mostly on the postsynaptic cell.  
A study by Weiler and Greenough (1993) showed that Group 1 mGluRs can trigger 
postsynaptic protein synthesis. They investigated the rate at which ribosomes loaded onto 
mRNA to form polyribosomal aggregates. It was found that exogenous application of 
glutamate activated Group 1 mGluRs accelerated the incorporation of [35S] methionine 
indicating protein synthesis. Another study showed evidence that Group 1 mGluRs were 
triggering protein synthesis (Raymond et al., 2000). This study investigated the effect of 
mGluR-mediated priming on LTP in hippocampal slices from young adult Sprague Dawley 
rats. It was hypothesised that activation of Group 1 mGluRs could prime LTP in a de novo 
protein synthesis dependent manner. Initially, DHPG was applied in bath medium for 30 
minutes and then washed out before TBS. Priming with DHPG caused an initial LTD but 
significantly increased subsequent LTP compared to controls. In order to test the hypothesis 
that Group 1 mGluRs are promoting protein synthesis, a Group 1 mGluR antagonist (AIDA) 
and protein synthesis inhibitor (emetine) were applied before and during the time of DHPG 
priming. Both AIDA and emetine completely blocked the enhancement of LTP previously 
seen with priming. This result suggested that activation of Group 1 mGluR during the 
priming phase was enhanced subsequent LTP via in a de novo protein synthesis dependent 
manner. When emetine was applied 10 minutes before, during, and for 10 minutes after the 
TBS, the priming effect of DHPG was blocked. However, if emetine was applied later at 20 
minutes after TBS, then there was no effect on the priming of LTP. When transcriptional 
inhibitor actinomycin-D was added 20 minutes prior and during DHPG priming, it had no 
effect on the LTP. From this it was concluded that Group 1 mGluRs were translating new 
proteins from existing mRNA without any new transcription. From these findings, it was 
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concluded that Group 1 mGluRs can prime LTP through synthesis of new proteins and that 
this synthesis occurs swiftly after application of DHPG.   
Protein kinase p90rsk is a key component in the protein translation complex. 
Investigation by Angenstein et al. (1998) showed that stimulation of Group 1 mGluRs 
resulted in increased phosphorylation of a set of polyribosome-binding proteins indicating 
possible protein translation in neurons. Activation of mGluRs induced a protein kinase C 
dependent translocation of p90rsk to polyribosomes. This process was suggested to occur 
through phosphorylating and inhibiting GSK-3β. The authors concluded that mGluRs may 
act by priming protein synthesis via protein kinase p90rsk translocation to polyribosomes 
resulting in phosphorylation of gsk-3β. 
A point of interest in this study is the interaction between Group 1 mGluRs and α-
secretase. Both sAPPα and DHPG have shown to increase protein synthesis in hippocampal 
cells (Claasen et al., 2009; Wang et al., 2016). This common action of sAPPα and DHPG 
raises the question of whether they act through the same pathway to achieve this result. Lee et 
al. (1995) showed that stimulation of mGluRs could lead to an increase in sAPPα and 
hypothesised that it was due to an increase in α-secretase activity. Quisqualic acid (Group 1 
mGluR agonist) stimulation also lead to an increase in sAPPα production (Jolly-Tornetta et 
al., 1998). These studies showed that mGluRs can affect the production of sAPPα via α-
secretase and therefore it is of interest to determine if mGluRs increase protein synthesis 
through increased sAPPα production. 
Therapeutic Potential of sAPPα and its functional domains 
The observed neuroprotective and neurotrophic properties of sAPPα have led to 
suggestions that it may be a useful therapeutic agent for the treatment of neurological 
disorders such as AD. For example, one of the hallmarks of AD is memory loss. sAPPα has 
been found to reverse memory loss in AD rat models (Hick et al., 2015). 
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One of the major problems with proteins or peptides being used as a therapeutic agent 
in the brain is the challenge of getting to the target location. The two main barriers that 
separate the CNS from the periphery are the blood brain barrier (BBB) and the blood-
cerebrospinal fluid barrier (B-CSF-B) (Bickel et al., 2001). These two barriers are responsible 
for different tasks and therefore are anatomically and physiologically different. The BBB is 
located at the endothelial cells of the brain tissue capillaries while the B-CSF-B is located at 
the choroid plexus and the circumventricular organs. The BBB is a thin, membranous 
structure and its function is to provide the essential nutrients and maintain the internal milieu 
within the CNS. The endothelial cells are connected by tight-junctions forming a high-
resistance barrier which acts as the main diffusion barrier for solutes. On the other hand, the 
B-CSF-B is lacking endothelial tight junctions making it a secreting epithelium with leaky 
capillaries. In order to reach the brain, proteins must be able to cross the BBB  
Therefore, for sAPPα to be useful as a therapeutic target, methods of administration to 
the CNS must be explored. An invasive procedure for drug delivery would involve direct 
administration into the CNS via surgical methods. In contrast, non-invasive methods can be 
employed for drug administration. Pharmacologically changing the permeability of the BBB 
would increase the chances of peptides or proteins crossing into the CNS.  
One of the most studied techniques for this is via the use of a protein transport vector 
coupled to the protein or peptide of interest to form a chimeric peptide. This chimeric peptide 
binds to the luminal plasma membrane of the endothelial cells via a cell surface receptor. 
Once bound, transcytosis is initiated which results in the chimeric peptide being released into 
the brain extracellular fluid. Once across the BBB, a cleavable linker between the peptide and 
transport vector is employed and tissue enzymes can separate the two. This results in a free 
peptide or protein that can interact with the specific receptor on brain cells (Bikel et al., 
2001). 
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There is also reason to focus on peptides over proteins in terms of therapeutic agents. 
Peptides are smaller than proteins in terms of molecular size and therefore are less susceptible 
to physical and chemical degradation. Smaller peptides also cross through the epithelial layer 
more easily (McMartin et al., 1987). 
The sAPPα molecule contains several short sequences of amino acids that may have 
some therapeutic value. A tri-peptide chain RER which is found within sAPPα and sAPPβ, 
has been found to have neuroprotective and neurotropic properties (Mileusnic & Rose, 2011). 
A second sequence of interest is the previously mentioned 16 amino acid C-terminal peptide 
(CTα16) which distinguishes sAPPα from the shorter sAPPβ. Due to the distinct difference 
between the neuroprotective and neurotropic properties of these two soluble proteins, the 
peptide chain that differentiates them has been investigated to determine if it alone exhibits 
similar properties to full length sAPPα. 
Morrissey et al. (2019a) investigated the effect of RER and sAPPα on LTP and 
protein synthesis in rat hippocampus. That study found that RER enhanced the induction and 
persistence of LTP in vitro in CA1 of rat hippocampal slices in a similar manner to sAPPα. 
As previously stated, sAPPα displays a concentration dependent effect on LTP enhancement. 
In order to see if RER has the same properties as sAPPα, RER was used in place of sAPPα at 
different concentrations. The results showed that RER had a concentration dependent effect 
with optimum concentration at around 10nM. To test whether the RER sequence was 
necessary for sAPPα to have its effects, a modified version of sAPPα was created where the 
RER sequence was replaced with AAA; AAA was used as it was relatively inactive. The 
sAPPαAAA molecule did not have any effect on the induction or persistence of LTP 
compared to control. AAA as a standalone tripeptide was tested to make sure it did not have 
any effect on LTP. AAA produced no effect on induction or persistence on LTP therefore 
suggesting that it is specifically the RER sequence that is necessary for LTP enhancement in 
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sAPPα. It was also found that the LTP enhancement produced by RER was protein synthesis 
dependent as it was blocked by the presence of cycloheximide. Once again administration of 
cycloheximide by itself had no effect on basal levels of LTP.   
Morrissey et al. (2019b) conducted another study, this time investigating the effects of 
the 16 amino acid peptides at the C terminus of sAPPα (CTα16). Results from this study 
showed that CTα16 produced enhancements in LTP in a similar manner to sAPPα. CTα16 
had no effect in paired pulse facilitation test in the presence of D-AP5 indicating that like 
sAPPα, its effects were most likely postsynaptic. Also, like sAPPα, the effects of CTα16 
were concentration dependent. It was found that CTα16 enhanced LTP at 1nM but not at any 
other concentrations tested (0.3nM, 10nM, 1uM). A scrambled version of CTα16 was also 
tested as a control and had no effects on LTP induction or persistence. Further modifications 
of the CTα16 molecule were also investigated. Altering the termini of peptides reduces their 
rate of degradation and is an important factor for potential drug therapies. The modified 
CTα16 molecule (Bn-CTα16-NH2) retained the ability to enhance LTP 60 minutes after 
TBS. Like sAPPα, CTα16 effects were found to be protein synthesis dependent, as its effects 
were blocked in the presence of cycloheximide. Treatment of CTα16 in an APP/PS1 mouse 
model of AD showed similar rescue effects compared to sAPPα restoring LTP back to WT 
levels (Morrissey et al., 2019b). 
Present study 
Although the studies discussed above have investigated sAPPα and Group 1 mGluRs 
and their effects on protein synthesis there are still gaps in our knowledge. There have been 
previous studies showing stimulation of mGluRs can enhance levels of sAPPα. However, 
these experiments were not Group 1 mGluR specific (Lee et al., 1995; Ulus & Wurtman, 
1997; Jolly-Tornetta et al., 1998). This study will target the Group 1 mGluRs using specific 
agonists and antagonists and try to look for a potential pathway of action between sAPPα and 
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Group 1 mGluRs. It will also investigate two peptides of interest for their potential role as a 
therapeutic agent against AD. Traditionally, protein synthesis levels are measured by 
flooding radioactive isotopes such as 35S-methionine which incorporate into newly 
synthesised proteins. Surface sensing of translation (SUnSET) is a different technique which 
uses puromycin to detect newly formed proteins. An antibiotic produced by Streptomyces 
alboniger, puromycin is a structural analogue of amino-acyl-transfer RNA. Therefore, it is 
incorporated into elongating peptide chains of newly synthesized proteins.  By adding low 
concentrations of puromycin to cells, a puromycin antibody can detect its levels via western 
blots.  The study will be broken down into five experiments each working on a different 
aspect of sAPPα. 
The first experiment will determine the effect of sAPPα on global protein synthesis. 
The protein synthesis inhibitor anisomycin will be used to test whether the SUnSET protocol 
being used is measuring de novo protein synthesis in rat CA1 hippocampal slices. For this 
experiment, it is hypothesised that exogenous sAPPα will increase protein synthesis 
compared to control and when treated together with anisomycin, the enhancement will be 
inhibited. This is based on previous work that showed that exogenous sAPPα causes an 
increase in protein synthesis (Claasen et al., 2009).  
It is hypothesised that that Group 1 mGluRs are working upstream of sAPPα. The 
second experiment will test the main hypothesised pathway of action between sAPPα and 
Group 1 mGluRs. DHPG will be used as a Group 1 mGluR agonist and TAPI-1 as an α-
secretase inhibitor. It is hypothesised that treatment with DHPG will significantly increase 
protein synthesis compared to control and for this effect to be inhibited by TAPI-1 indicating 
that α-secretase is working downstream of Group 1 mGluRs. 
The third experiment will test the reverse pathway whereby Group 1 mGluRs are 
working downstream of sAPPα. It will use exogenous sAPPα and the mGluR antagonist 
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LY341495, which at micromolar concentrations has been shown to inhibit Group 1 mGluRs 
(Kingston et al., 1998). It is hypothesised that exogenous sAPPα will increase protein 
synthesis and when treated together with LY341495, the enhanced effect would remain.  
The fourth experiment will investigate how similar RER is to sAPPα in terms of 
enhancing protein synthesis. RER will be administered at two different concentrations. A 
strain of sAPPα where the RER peptide chain is replaced with AAA as well as an isolated 
AAA peptide will be investigated. It is hypothesised that RER peptide at both concentrations 
will be able to increase protein synthesis in a similar manner to sAPPα and that RER will be 
both sufficient and required for the enhancement of protein synthesis.  
The fifth experiment will investigate the peptide chain that accounts for the difference 
between sAPPα and sAPPβ in CTα16. The isolated CTα16 will be administered at two 
different concentrations. A scrambled version of CTα16 and sAPPβ will also be used in this 
experiment. It is hypothesised that both concentrations of CTα16 will significantly increase 
protein synthesis compared to control in a comparable manner to full length sAPPα while the 
scrambled version and sβ will have no effect on protein synthesis.  
All experiments will be done on CA1 hippocampal mini slices from rats and the 
SUnSET western blot protocol will be used to measure global protein synthesis. Overall there 
are two main hypotheses in this present study. Firstly, it is hypothesised that Group 1 mGluR 
mediated activation of α-secretase is a mechanism by which glutamatergic neural activity can 
stimulate sAPPα cleavage and protein synthesis. Secondly, both RER and CTα16 peptides 
will be both sufficient and required to enhance protein synthesis in a similar manner to full 









The animals used in this study were 6-8-week-old male and Sprague Dawley rats. The 
rats were housed at the University of Otago, Department of Psychology within a controlled 
environment; kept in open top cages within a ventilated room. All animals were handled with 
care and experiments were carried out in strict accordance with the ‘University of Otago 
Code of Ethical Conduct for the Manipulation of Animals’, specifically under the ET19/16 
protocol.  
Slice Preparation 
The rats were anaesthetised with ketamine (100 mg/kg, i.p.) and then decapitated by 
guillotine. The whole brain was removed, and the complete hippocampus was isolated over 
ice. The hippocampus was then stored in ice-cold cutting solution (210 mM sucrose, 26 nM 
NaHCO3, 20 mM D-glucose, 2.5 mM KCL, 1.25 mM NaH2PO4, 0.5 mM CaCl2, 3 mM 
MgCl2). Using a tissue chopper, 400 µm transverse slices were cut and placed in a tissue 
chamber and incubated in oxygenated artificial cerebrospinal fluid (aCSF; 124 mM NaCl, 3.2 
mM KCl, 1.2 mM NaH2PO4, 26 mM NaHCO3, 2.5 mM CaCl2, 1.3 mM MgCl2, 10 mM D-
glucose). From these slices, CA1 mini-slices (Fig. 2) were prepared by hand using a sharp 
blade under the guidance of a microscope. Once the mini-slices were made, they were 
separated into the experimental groups. The slices were incubated in aCSF in wells (4 ml) at 
32oC for two hours. After this incubation, the aCSF was replaced with the respective drug for 
30 minutes. After the 30-minute drug administration, the slices were removed from the wells 








Figure 2. Image of CA1 hippocampal mini-slice. From the image of a transverse 
hippocampal slice cut up and CA1 mini-slice labelled. Scale is approximate.  
Experiment Design 
This study was broken down into five main experiments. The hippocampal mini-slices 
were placed in different drugs in each experiment and the effect on protein synthesis was 
measured. A within-subject design was used meaning that all animals in each experiment 
were exposed to all treatments. Across all experiments, 40 μl of puromycin (10 μl/ml) was 
added into all groups during the drug incubation.  
Experiment 1 had four groups. Group 1 was a control where the aCSF was replaced 
with new aCSF, group 2 received sAPPα (final conc. 1 nM), group 3 received anisomycin 
(final conc. 40 μM), and group 4 received both sAPPα and anisomycin.  
Experiment 2 had four groups. Group 1 was control where the aCSF was replaced 
with new aCSF, group 2 received DHPG (final conc. 20 μM), group 3 received TAPI-1 (final 
conc. 20 μM), and group 4 received both DHPG and TAPI-1.  
Experiment 3 had four groups. Group 1 was a control where the aCSF was replaced 
with new aCSF, group 2 received sAPPα (final conc. 10 nM), group 3 received LY341495 
(final conc. 100 μM), and group 4 received both sAPPα and LY341495.  
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Experiment 4 had six groups. Group 1 was a control where the aCSF was replaced 
with new aCSF, group 2 received sAPPα (final conc. 10 nM), group 3 received RER (final 
conc. 1 nM), group 4 received RER (final conc. 10 nM), group 5 received sAPPα-AAA (final 
conc. 1 nM), and group 6 received AAA (final conc. 10 nM).  
Experiment 5 was broken down into two sub experiments. 5a had four groups. Group 
1 was a control where the aCSF was replaced with new aCSF, group 2 received CTα16 (final 
conc. 1 nM), group 3 received CTα16 (final conc. 10 nM), and group 4 received the 
scrambled variant of CTα16 (final conc. 10 nM). 5b had three groups. Group 1 was a control 
where the aCSF was replaced with new aCSF, group 2 received sAPPα (final conc. 1 nM), 
and group 3 received sAPPβ (final conc. 1 nM).  
Slice preparation and incubation were performed by Bruce Mockett, Department of 
Psychology, University of Otago and the groups for all experiments were blinded.  
Protein Extraction & Protein Assay 
After the mini-slices were collected and snap frozen, protein extraction took place. 
This experiment used a protein extraction solution (20 µl egtazic acid (EGTA 0.5 M), 20 µl 
ethylenediaminetetraacetic acid (EDTA 0.5 M), 9.75 ml phosphate-buffered saline (PBS 0.2 
M), 10 µl phenylmethylsulfonyl fluoride (PMSF 0.1 M) 100 µl 10% sodium dodecyl sulfate 
(SDS), 100 µl Triton-X, 1 mini-complete tablet). The protein extraction solution (PES) was 
then added to each sample tube (100 µl). The frozen CA1 mini-slices were homogenized into 
the PES using plastic rods and sonication (QSonica, serial number: 85453W-06-15, 10 x 1 
sec pulses at 55% power). Once all the samples were dissolved fully into the solution, a 
bovine serum albumin (BSA) assay was performed. 
Five BSA standards were made up: 0, 0.25, 0.5, 1, 2 mg/ml into five Eppendorf tubes 
via serial dilution. At each stage of dilution, the Eppendorf tubes were vortexed.  
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In a 96 well plate, triplicate 5 µl samples of each BSA standard were added. 2 µl of each 
sample were then added in duplicate, diluted by adding 3 µl of PES. 25 µl of Solution A 
(Bio-Rad, New Zealand) and 200 µl of solution B (Bio-Rad, New Zealand) was added to 
each well. The well plate was then put into an iMark Microplate Reader (Bio-Rad, appliance 
number: 0007195408) and shaken for five seconds then was left to incubate for 15 minutes. 
After incubation, the plate was read at 750 nm. 
From the results of the plate reader, a BSA standard curve was produced. Using the 
equation of the trendline of the BSA standards, the protein concentration of the samples were 
calculated. Due to the samples being diluted 2/5 (2 µl of sample and 3 µl of PES), the results 
were multiplied by 2.5 to give accurate concentration. The concentration required for 20 µg 
of protein in each sample for the western blots was calculated in preparation for the western 
blot.  
SUnSET (western blots) 
Day 0- 12% gels were made up; 3.5 ml Milli-Q (MQ), 2.5 ml 4x lower buffer, 4 ml 
30% Bis/Acryl, 50 µl 10% ammonium persulfate (APS) and 5 µl N,N,N',N'-
tetramethylethane-1,2-diamine (TEMED). This solution was then pipetted into a western blot 
cassette and filled up two thirds and the remaining third was made up with MQ. The cassette 
was left to set at room temperature for 30 minutes and then wrapped with paraffin film and 
stored in the refrigerator overnight.  
Two buffer solutions were also prepared. The running buffer (1x) which fills the 
western blot box for electrophoresis was prepared by diluting 100 ml of stock running buffer 
(10x) and made up to 1 L MQ. The transfer buffer was prepared with 40 ml of NOVEX 
solution and 150 ml of methanol and made up to 1 L with MQ.  
Day 1- The gels were taken out of the refrigerator and left at room temperature for 30 
minutes. After 30 minutes, the paraffin film was removed from the cassette and the MQ was 
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cleaned out. The stacking gel (5%) was prepared: 1.44 ml MQ, 625 µl 4x upper buffer (used 
to form the top layer in the cassette), 420 µl 30% Bis/Acryl, 12.5 µl 10% APS, 2.5 µl 
TEMED and loaded into the cassette on top of the gel. A loading comb was then placed on 
top of the cassette and was left to set for 15 minutes. The loading buffer (solution for one 
sample): 1.5 µl 10x sample buffer, 3.5 µl bromophenol blue, 0.175 µl β-mercaptoethanol was 
prepared. Each sample (concentration calculated in BSA assay) was made up to 20 µg into 
Eppendorf tubes (e.g. if concentration is 5.6 µg/µl then 3.6 µl of sample + 6.4 µl MQ. 5 µl of 
loading buffer added to each sample to make 15 µl of total solution). These samples were 
then placed in a block heater (Eppendorf AG, serial number: 5382DJ804498) at 99oC for ten 
minutes. This was followed up with a short spin in a centrifuge machine (Eppendorf AG, 
serial number: 5453CK771165). 
The combs were removed from the cassette to expose the 10 wells created which were 
then rinsed with the running buffer. Cassettes were placed in the NOVEX box (BIO RAD 
New Zealand) and filled with running buffer. Lane 1 was loaded with rainbow marker and 
lanes 2-9 were loaded with experimental groups. Lane 10, if used, was loaded with no 
puromycin control as that lane tended to curve off to the side and not get a great reading after 
electrophoresis. The gel was run at 125 V (constant volts) for 90 minutes. 
While electrophoresis was running, the transfer blot was prepared. Five sponges and two 
nitrocellulose membranes were soaked in 1 L of transfer buffer in a plastic box. Air bubbles 
were removed from sponges and the plastic box was placed in the refrigerator. Two pieces of 
filter paper per gel were also prepared. 
Once the gel had completed running, the cassettes were removed from the NOVEX 
box. NOEVX box was rinsed in preparation for transfer protocol. The cassettes were opened, 
and the gel removed using a spatula tool. The gel was rinsed with transfer buffer and one 
piece of the prepared filter paper was dipped into the transfer buffer and positioned on top of 
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the gel. A tube was used to remove any air bubbles between the gel and filter paper. The gel 
and filter paper were then put on a flat surface with the gel side exposed. Nitrocellulose 
membrane was then placed on top of the gel and air bubbles were removed. The remaining 
filter paper was dipped in transfer buffer then positioned on top of the membrane and air 
bubbles were removed with tube. This was repeated for the other gel. Two out of the five 
prepared sponges were placed at the bottom of the blot module, followed by one gel 
sandwich, one sponge, the other gel sandwich, and finally two sponges. The blot module was 
then placed inside the NOVEX box and filled with transfer buffer and ran at 100mA 
(constant amps) for 120 minutes. 
Blots were removed from the blot module and rinsed in PBS no Tween. Blots were 
then cut to appropriate size based on the rainbow marker in lane one. Once cut up, the blots 
were incubated in Odyssey blocking buffer (50 ml) for one hour with gentle shaking. Primary 
antibody was prepared in 5 ml of PBS Tween with 0.1% BSA and 0.1% NGS e.g. for 5 ml; 
0.75 µl tubulin antibody, 5 µl puromycin antibody (Kerafast Inc., Cat: EQ0001, 1.36 mg/ml), 
50 µl 10% BSA, and 5 µl normal goat serum (NGS). Blots were incubated in primary 
antibody at 4oC for 24 hours with gentle shaking.  
Day 2- Secondary antibody; IRDye goat anti-rabbit 680 (LI-COR, Lot# C60606-05) 
and IRDye goat anti-mouse 800 (LI-COR, Lot# C60920-05), were diluted 1:10,000 and 
1:15,000 respectively in 50 ml of PBS Tween and protected from light in foil covered falcon 
tube. Blots taken out of incubation in primary antibody and washed 3 x 5 minutes in PBS 
Tween. Following wash, blots were incubated in secondary antibody covered with foil to 
protect from light for 1 hour with light shaking. After secondary antibody incubation, the 
blots were washed 3 x 5 minutes in PBS Tween followed by 1 x 5 minutes in PBS without 
Tween. Blots then placed into PBS no Tween in a light protected container for transport to 
Odyssey Fc scanner. 
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Image Capture and Analysis 
Blots were individually placed in the Odyssey Fc (LI-COR Biosciences) scanner for 
image capture. Images were taken at 700 nm and 800 nm for tubulin and puromycin 
detection, respectively and analysed using Image Studio. Both 700 nm and 800 nm images 
were individually analysed using the analysis box tool to compare the darkness of the signal 
compared to the background. Two rectangular boxes were created, and the formula used was 
Signal = total – (background x area). This was repeated for all lanes for both tubulin and 
puromycin. Once all these values were calculated, the data were exported to a spreadsheet. 
From the spreadsheet, the data from each lane was further analysed. The puromycin values 
were divided by the tubulin values then multiplied by 1,000 to give a normalised to tubulin 
(loading control) value. From there the blinded codes for each sample group were revealed 
and all samples from the same animal were normalised to the control. This resulted in a 
control value of one and every other experimental group a value comparable to control 
showing either a decrease or increase in protein synthesis. 
 In some cases, blots were excluded from results due to them being compromised in 
certain ways. Some examples include poor antibody detection, lanes being merged and 
physical damage to the gel.  
Statistical Analysis  
Data was collected from the Odyssey Fc scanner and exported through Microsoft 
Excel into a spreadsheet. These values were then analysed using GraphPad Prism 8.0. 
Differences across treatment groups were assessed using a one-way ANOVA. This was 
followed up with a Bonforoni post-hoc test to compare the difference between certain 
treatment groups and significance was assessed at p < 0.05. 
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Drugs and Reagents 
All salts used in aCSF and slice preparation were purchased from Merck Millipore 
(Billerica, MA). DHPG, TAPI-1, LY341495 and anisomycin were all purchased from Torcis 
Bioscience (Minneapolis, MN). Puromycin was purchased from Sigma-Aldrich (St Louis, 
MO). sAPPα and sAPPβ were produced in-house using HEK 293T cells as previous 
described (Turner et al., 2007). All three of the CTα16 peptide (sequence ac-
DAEFRHDSGYEVHHQK), its scrambled variant (sequence ac-AHYQESVHEFDKGDHR) 
and the RER peptide were produced by EZBiolab (Carmel, IN). All other reagents used in 
protein extraction and western blots were purchased from Bio-Rad Laboratories (Hercules, 
CA).  



















1. sAPPα increases global protein synthesis 
The aim of this experiment was to determine the effect of sAPPα on global protein 
synthesis using the SUnSET technique. To achieve this, sAPPα (1 nM) was added to CA1 
mini slices for 30 minutes as we have done in previous electrophysiological studies 
(Morrissey et al., 2019a,b). The presence of sAPPα increased protein synthesis. Levels of 
protein synthesis measured through the amount of puromycin detectable in each group was 
significantly increased in the sAPPα group compared to control (n=6, p=0.0156, Fig 4). 
To establish whether the SUnSET protocol was measuring de novo protein synthesis, 
the protein synthesis inhibitor anisomycin was used. Anisomycin (40 μM) was applied to 
slices for 30 minutes, which were then snap frozen on dry ice. The presence of anisomycin 
resulted in puromycin levels comparable to the control group (n= 6, p=>0.9999, Fig 4). 
To demonstrate if sAPPα was promoting protein synthesis, slices were treated with 
both sAPPα and anisomycin. As expected, the presence of anisomycin significantly inhibited 
the increase in protein synthesis shown by the sAPPα group (n=6, p=>0.9999, Fig. 4). 
Treatment with anisomycin by itself did not have any significant effect on basal protein 
synthesis (n=6, p=>0.9999, Fig. 4). 
Taken together, the results from this experiment support the hypothesis that sAPPα 
increases protein synthesis in CA1 hippocampal mini-slices and the SUnSET technique is a 






















Figure 3. sAPPα and anisomycin western blot images. A. A representative western blot 
image of α-tubulin loading buffer across all groups in experiment 1. B. A representative 
western blot image of total puromycin signal across all groups in experiment 1. (C= control 
group, ANI= anisomycin group, ANI+S= anisomycin + sAPPα group, S= sAPPα group, 
























Total puromycin  
A 
B 
C     ANI   ANI+S   S       
C     ANI ANI+S   S       






Figure 4. sAPPα increases global protein synthesis which can be blocked by anisomycin. 
Histogram showing relative increases or decreases in puromycin signal. Changes in groups 
were calculated by taking total signal normalised to tubulin and then normalised to the 
control group. Data was analysed using a one-way ANOVA followed up by a Bonferroni 
post-hoc test. Slices treated with sAPPα 1 nM significantly increased the number of newly 
synthesised proteins compared to slices in the control group (n=6, p=0.0156). This increase 
was blocked by the addition of protein synthesis inhibitor anisomycin. The slices treated with 
both sAPPα and anisomycin had no significant difference when compared to the control 
group (n=6, p=>0.9999). The data points are displayed as mean ± standard error of the mean. 
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2. DHPG increases global protein synthesis which is inhibited by TAPI-1 
 Group 1 mGluR activity has been shown to increase protein synthesis in the 
hippocampus (Weiler & Greenough, 1993; Raymond et al., 2000). In this experiment, the 
Group 1 mGluR agonist DHPG (20 μM) was added to examine what effect an increase in 
Group 1 mGluR activity has on protein synthesis. As expected, DHPG increased protein 
synthesis significantly compared to the control group (n= 6, p=0.0016, Fig. 6) 
To investigate our hypothesis that the Group I mGluR-mediated increase in protein 
synthesis is in turn mediated through an increase in sAPPα production, we activated mGluRs 
with DHPG in the presence of the α-secretase inhibitor TAPI-1 (20 μM) to block sAPPα 
production via APP cleavage. By itself, TAPI-1 showed no difference compared to the 
control group (n=6, p=>0.9999, Fig. 6).  When both DHPG and TAPI-1 was added together, 
the effect of DHPG was inhibited and there was no significant increase compared to the 
control group (n= 6, p=>0.999, Fig. 6).  
Results from this experiment suggest that α-secretase and therefore sAPPα is working 





























Figure 5. DHPG and TAPI-1 western blot images. A. A representative western blot image of 
α-tubulin loading buffer across all groups in experiment 2. B. A representative western blot 
image of total puromycin signal across all groups in experiment 2. (C= control group, 
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Figure 6. DHPG increases global protein synthesis which can be blocked by TAPI-1. 
Histogram showing relative increases or decreases in puromycin signal. Changes in groups 
were calculated by taking total signal normalised to tubulin and then normalised to the 
control group. Data was analysed using a one-way ANOVA followed up by a Bonferroni 
post-hoc test. Slices treated with DHPG significantly increased levels of newly synthesised 
proteins compared to control (n=6, p=0.0016). Slices treated with both DHPG and TAPI-1 
had no significant difference compared to control (n=6, p=>0.9999). The data points are 
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3. sAPPα increases global protein synthesis which is not inhibited by LY 
In the TAPI-1 experiment, the results suggested that α-secretase was working 
downstream of Group 1 mGluRs. To give this more validity, a reverse experiment was 
conducted. Exogenous sAPPα (1 nM) and the Group 1 mGluR antagonist LY341495 (100 
μM) were added to the slices. The addition of LY341495 had no significant effect on protein 
synthesis compared to control (n= 6, p=>0.9999, Fig. 8). As expected, the addition of 
exogenous sAPPα significantly increased protein synthesis compared to control (n=6, 
p=0.0022, Fig. 8). When slices were treated with both exogenous sAPPα and LY341495, the 
effects of sAPPα were not inhibited and this group had significantly increased levels of newly 
synthesised proteins compared to the control group (n=6, p=0.0395, Fig. 8). These results 
support the previous experiment’s findings that α-secretase & sAPPα is working downstream 




























Figure 7. sAPPα and LY341495 western blot images. A. A representative western blot image 
of α-tubulin loading buffer across all groups in experiment 3. B. A representative western 
blot image of total puromycin signal across all groups in experiment 3. (C= control group, S= 
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Figure 8. sAPPα increases global protein synthesis even in the presence of LY341495. 
Histogram showing relative increases or decreases in puromycin signal. Changes in groups 
were calculated by taking total signal normalised to tubulin and then normalised to the 
control group. Data was analysed using a one-way ANOVA followed up by a Bonferroni 
post-hoc test. Slices treated with sAPPα had significantly increased levels of newly 
synthesised proteins compared to the control group (n=6, p=0.0022). Slices treated with both 
sAPPα plus LY341495 was also significantly different compared to the control group (n=6, 
p=0.0395). The data points are displayed as mean ± standard error of the mean. *Significant 
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4. RER tripeptide increases global protein synthesis in a similar manner to sAPPα 
RER is required to enhance protein synthesis 
 To test whether RER is required for sAPPα to enhance protein synthesis, sAPPα-
AAA (RER tripeptide replaced with three alanine) was used. Slices treated with sAPPα-AAA 
(1 nM) had no significant difference in protein synthesis compared to the control group (n=7, 
p=0.9324, Fig. 10). Slices treated with AAA (10 nM) tripeptide by itself also had no 
significant effect on protein synthesis (n=7, p=>0.999, Fig. 10).  
RER is sufficient to enhance protein synthesis at both concentrations 
In this experiment, the RER tripeptide of sAPPα was investigated to see if it could 
mimic the effects of full length sAPPα by itself. Firstly, slices treated with sAPPα showed the 
expected increase in protein synthesis compared to control (n=7, p=0.0134, Fig. 10). The 
effects of sAPPα have been found to be concentration dependent (Claasen et al., 2009) and 
therefore two concentrations of RER were used; 1 nM and 10 nM which is in line with 
previous experiments investigating RER (Morrissey et al., 2019a). Both 1 nM and 10 nM 
concentrations of RER showed a significant increase compared to the control group (n=7, 
p=0.0259 and n=7, p=0.0118 respectively, Fig. 10). 
Findings from this experiment suggest that RER is required for sAPPα to increase 
protein synthesis, but when isolated, can mimic the effects of full length sAPPα in enhancing 
























Figure 9. sAPPα and RER western blot images. A. A representative western blot image of α-
tubulin loading buffer across all groups in experiment 4. B. A representative western blot 
image of total puromycin signal across all groups in experiment 4. (C= control group, S= 
sAPPα group, RER 1= RER1 nM group, RER10= RER 10 nM group, S-AAA= sAPPα-AAA 
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Figure 10.  RER increases global protein synthesis at both concentrations. Histogram 
showing relative increases or decreases in puromycin signal. Changes in groups were 
calculated by taking total signal normalised to tubulin and then normalised to the control 
group. Data was analysed using a one-way ANOVA followed up by Bonferroni post-hoc test. 
Slices treated with sAPPα had a significant increase in newly synthesised proteins compared 
to the control group (n=7, p=0.0134). Both RER 1 nM and RER 10 nM also significantly 
increased levels of newly synthesised proteins compared to the control group (n=7, p=0.0259 
and n=7, p=0.0118 respectively). Slices treated with sAPPα-AAA where the RER domain is 
replaced with three alanine had no effect on the levels of newly synthesised proteins 
compared to control (n=7, p=0.9324). Slices treated with AAA alone also had no significant 
difference compared to control group (n=7, p=>0.9999). The data points are displayed as 
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5. CTα16 increases protein synthesis in a similar manner to sAPPα 
CTα16 is required to increase in protein synthesis 
The peptide chain labelled CTα16 is the difference between sAPPα and sAPPβ. In this 
experiment, slices were treated with either sAPPα or sAPPβ to see the effects of the two 
proteins on protein synthesis. sAPPα showed the expected results and increased protein 
synthesis, while sAPPβ did not. Slices treated with sAPPα (1 nM) had a significant increase 
in protein synthesis compared to the control slices (n=5, p=0.0278, Fig. 12). sAPPβ (1 nM) 
treatment did not have a significant effect on slices compared to control (n= 5, p=0.2402, Fig. 
12).  
CTα16 is sufficient to enhance protein synthesis at both concentrations 
The difference between sAPPα and sAPPβ is an additional 16 amino acids at the C-
terminal of sAPPα. We have designated this sequence as CTα16 and investigated its 
properties. If CTα16 can mimic the positive effects of full length sAPPα, it could be 
beneficial for therapeutic purposes. To investigate if CTα16 can mimic the effect of sAPPα 
on protein synthesis, we treated slices with CTα16 at both 1 nM and 10 nM which is 
consistent with previous experiments investigating CTα16 (Morrissey et al., 2019b). Slices 
treated with CTα16 had significant increases in protein synthesis compared to control at both 
1 nM and 10 nM (n=8, p=<0.0009 and n=8, p=0.0293 respectively, Fig. 14). A scrambled 
version of CTα16 in which the amino acid sequence was randomised was also tested as a 
control. Results showed that slices treated with the scrambled CTα16 (10 nM) was not 
significantly different from control (n=8, p=>0.9999, Fig. 14). 
Results from this experiment showed evidence that CTα16 was required for sAPPα to 
increase protein synthesis and that CTα16 at both 1 nM and 10 nM concentrations can 
increase protein synthesis in a comparable manner to full length sAPPα.  
 


















Figure 11. sAPPα and sAPPβ western blot images. A. A representative western blot image of 
α-tubulin loading buffer across all groups in experiment 5a. B. A representative western blot 
image of total puromycin signal across all groups in experiment 5a. (C= control group, Sβ= 
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Figure 11. sAPPα increases global protein synthesis while sAPPβ does not. Histogram 
showing relative increases or decreases in puromycin signal. Changes in groups were 
calculated by taking total signal normalised to tubulin and then normalised to the control 
group. Data was analysed using a one-way ANOVA followed up by a Bonferroni post-hoc 
test. Slices treated with sAPPα significantly increased levels of newly synthesis compared to 
control (n= 5, p=0.0278). sAPPβ had no significant effect compared to control (n=5, 
p=0.2402). The data points are displayed as mean ± standard error of the mean. *Significant 






















Figure 13. sAPPα and CTα16 western blot images. A. A representative western blot image of 
α-tubulin loading buffer across all groups in experiment 5b. B. A representative western blot 
image of total puromycin signal across all groups in experiment 5b. (C= control group, CT1= 
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Figure 12. CTα16 increases protein synthesis at both concentrations. Histogram showing 
relative increases or decreases in puromycin signal. Changes in groups were calculated by 
taking total signal normalised to tubulin and then normalised to the control group. Data was 
analysed using a one-way ANOVA followed up by a Bonferroni post-hoc test. There was a 
significant increase in newly synthesised proteins in slices in both 1 nM CTα16 and 10 nM 
CTα16 compared to control (n=8, p=<0.0009 and n=8, p=0.0293). Slices treated with the 
scrambled variant of CTα16 had no significant difference in levels of newly synthesised 
proteins compared to the control (n=8, p=>0.9999. The data points are displayed as mean ± 












The present study explored two main hypotheses.  Firstly, a potential mGluR-
dependent pathway of action for sAPPα in promoting protein synthesis was explored. 
Secondly, two peptides derived from the sAPPα molecule were investigated to determine if 
they show similar effects as full length sAPPα in terms of enhancing protein synthesis in rat 
CA1 hippocampal slices. The results from this study support both hypotheses and is 
consistent with previous work.  
sAPPα and Group 1 mGluRs 
In the first experiment, slices treated with sAPPα had increased levels of puromycin 
incorporation implying increased rates of protein synthesis. The experiment supported the 
hypothesis that sAPPα increases protein synthesis. Although after this experiment it is not 
clear how exactly sAPPα increases protein synthesis, the addition of the protein synthesis 
inhibitor anisomycin inhibited the increase and therefore supported the use of the SUnSET 
protocol in measuring protein synthesis. This experiment also served to set a baseline for the 
effects of sAPPα relative to other treatments. 
A surprising result from this experiment was protein synthesis in the anisomycin 
group was not significantly less than the control group. Although this might seem 
paradoxical, there are a few reasons why this might be the case. The combination of low 
levels of proteins in the initiation phase at basal conditions and puromycin only being 
incorporated into a few newly formed proteins could cause a compounding factor towards 
anisomycin not affecting protein synthesis at basal levels. The SUnSET technique uses a very 
small amount of puromycin and therefore puromycin does not incorporate into every newly 
formed protein. This results in the western blot reflecting a short window of protein synthesis 
activity. Anisomycin inhibits protein synthesis at the initiation phase and not the elongation 
phase. Therefore, if the amount of proteins in the initiation stage is low at basal conditions, 
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the effects of anisomycin will be small. The reason for low levels of initiation could be due to 
the slices being put through the incubation phase. During this phase, basal protein synthesis 
would be occurring and therefore more proteins would be at the elongation phase by the time 
anisomycin was added. The reason that the effect of anisomycin can be seen in the group 
with both anisomycin and sAPPα could be that sAPPα promotes protein synthesis and 
therefore more proteins in this group would be in the initiation phase and therefore there 
would be more proteins for anisomycin to inhibit. The results of experiment one provides us 
with confidence in the SUnSET protocol for measuring global protein synthesis and provides 
support for sAPPα enhancing protein synthesis.  
The second experiment was designed to test whether Group 1 mGluRs and sAPPα are 
working in a serial pathway to promote protein synthesis. To achieve this, we treated slices 
with DHPG and TAPI-1. Treatment of slices with DHPG resulted in increased protein 
synthesis. This increase in protein synthesis caused by DHPG suggested that increased 
activation of Group 1 mGluRs can lead to increased protein synthesis, which is consistent 
with previous work (Raymond et al., 2000). Slices treated with TAPI-1 had no significant 
difference compared to basal levels protein synthesis. The most interesting result from this 
experiment was found in the slices treated with both DHPG and TAPI-1. When both DHPG 
and TAPI-1 were added together, there was no significant difference compared to control. 
This showed that even in the presence of a group1 mGluR agonist, an α-secretase antagonist 
inhibited the increased protein synthesis resulting in no significant difference compared to 
basal levels. These results support the hypothesised potential pathway of action for 
interaction between α-secretase and Group 1 mGluRs. The proposed pathway incorporated 
sAPPα activation down-stream of Group 1 mGluR activation and therefore an α-secretase 
inhibitor would block any effect a Group 1 mGluR agonist would have. If such a pathway of 
action is proposed, then the reverse also needs to be tested to further support the main 
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hypothesis. In this case, if sAPPα is not working downstream of Group 1 mGluR, it could be 
working upstream.  
Experiment three used the mGluR antagonist LY341495 and exogenous sAPPα. If 
sAPPα is acting upstream of Group 1 mGluR then the addition of LY341495 should inhibit 
the increase in protein synthesis that sAPPα induces. It was hypothesised that the addition of 
LY would not inhibit the sAPPα effects due to it working downstream of Group 1 mGluR. 
Slices treated with exogenous sAPPα had significantly increased levels of protein synthesis 
compared to control. This finding was consistent with experiment one which showed the 
beneficial effects of sAPPα such as neurogenesis were de novo protein synthesis dependent. 
Slices treated with LY341495 had no significant difference compared to control. The main 
finding was in the slices that were treated with both LY341495 and exogenous sAPPα. These 
slices had significant increases in protein synthesis comparable to the sAPPα alone group. 
These findings indicate that even when group1 mGluR activity is inhibited, the addition of 
exogenous sAPPα increased protein synthesis. Ireland and Abraham (2009) used the same 
concentration of LY341495 (100 μl) to show it inhibiting the effects of DHPG. Therefore, 
even though LY341495 had no effect here, it is an effective Group 1 mGluR antagonist at 
this concentration.  
Previous experiments have shown a link between mGluRs and sAPPα. Stimulation of 
mGluRs accelerated APP cleavage into sAPPα (Lee et al., 1995; Jolly-Tornetta et al., 1998). 
These studies proposed that PKC activity could be promoted via the stimulation of mGluRs 
which leads to a promotion of α-secretase activity therefore increased production of sAPPα 
(Bandyopadhyay et al., 2007). Both experiments two and three support the idea for the 
hypothesised pathway of action for sAPPα and Group 1 mGluR. With the upstream action of 
Group 1 mGluR leading to the cleavage of APP into sAPPα. 
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RER & CTα16 
Experiments four and five were designed investigate potential peptides of sAPPα that 
could mimic the effects of full length sAPPα. 
Previous work on the RER peptide have shown promising results mimicking the 
effects of sAPPα in electrophysiological experiments (Morrissey et al., 2019a). In experiment 
four, RER at both 1 and 10 nM showed comparable effects as sAPPα in terms of increases in 
protein synthesis, whereas neither the control peptides AAA or sAPPα-AAA had a significant 
effect compared to control. Both RER groups showed evidence to suggest that it is sufficient 
by itself to mimic the effects of sAPPα. The AAA and sAPPα-AAA groups failure to increase 
protein synthesis also supports the hypothesis that the RER tripeptide alone is enough to 
increase protein synthesis. These findings support our hypothesis and are aligned with RER’s 
ability to increase LTP (Morrissey et al., 2019a). RER has also been found to protect against 
memory loss induced by amyloid-beta in young chicks (Mileusnic et al., 2004). RER’s ability 
to increase protein synthesis and LTP might be a key factor in this trait.  
Experiment five focused on the C-terminal peptide CTα16. The hypothesis that 
CTα16 is both enough and necessary to produce increases in protein synthesis in a similar 
manner to sAPPα was supported. The first sub experiment with sAPPα and sAPPβ supported 
the previous experiments findings showing that sAPPα significantly increased protein 
synthesis compared to control while sAPPβ did not. As mentioned previously, CTα16 is the 
peptide chain that differentiates between sAPPα and sAPPβ and therefore this result shows 
evidence to support that the CTα16 peptide is required for the enhancement in protein 
synthesis produced by sAPPα. 
The second sub experiment showed that CTα16 was able to significantly increase 
protein synthesis at both 1 and 10 nM concentrations. This ability to increase protein 
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synthesis was consistent with slices treated with full length sAPPα and therefore CTα16 may 
be useful as a therapeutic agent in AD treatment.  
ScrCTα16 did not cause a significant difference compared to control. This shows 
evidence to support that these 16 amino acids are not only required, but the order is important 
for its ability to increase protein synthesis. Due to the scrambled nature, if only the amino 
acids were important, a similar enhancement of protein synthesis would be seen. These 
findings were in line with previous research using these peptides in LTP experiments which 
showed that CTα16 significantly increased LTP while its scrambled counterpart did not 
(Morrissey et al., 2019b). 
Strengths and Limitations  
A strength of this study was its novelty. No other study has investigated a link 
between Group 1 mGluRs and sAPPα using the SUnSET technique. These experiments have 
yielded novel results indicating a serial pathway of action between Group 1 mGluRs and 
sAPPα in regulating protein synthesis. Additionally, findings across all five experiments were 
consistent with previous literature where applicable. For example, it was shown that sAPPα 
can increase protein synthesis (Claasen et al., 2009) as well as DHPG increasing protein 
synthesis (Raymond et al., 2000).  
Another strength of the present study was the use of previously studied peptides. Both 
RER and CTα16 were peptides of interest with previous literature. LTP experiments have 
shown that both peptides were able to increase protein synthesis in a sAPPα like manner 
(Morrissey et al., 2019a,b) and those results are consistent in our protein synthesis SUnSET 
experiments.  
A limitation to this current study involved the shortcomings of the SUnSET 
technique. As previously mentioned, the SUnSET uses puromycin incorporation to indicate 
global protein levels and this in turn can be inferred as increases or decreases in the rate of 
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protein synthesis. However, due to the low concentration of puromycin into the CA1 
hippocampal mini-slices and only 30 minutes of treatment, it only provides a short time 
frame of the protein synthesis in each treatment group. However, the 30 minutes of treatment 
was used because previous studies have shown that this is sufficient time for sAPPα to have 
its effects (Abraham & Williams, 2003; Claasen et al., 2009). The concentration and short 
treatment time could compound and cause the results from this protocol to be not as accurate 
as it would if measured over a longer time. Although previous research has found that 
SUnSET was comparable to traditional measures of protein synthesis such as using a 
radioactive isotope (Goodman & Hornberger, 2013; Dadehbeigi & Dickson, 2013) there still 
are some limitations to consider. One of the limitations of SUnSET and the use of puromycin 
is that it only measures relative rates or changes in protein synthesis. This is different to the 
traditional isotope techniques which have been shown to be able to indicate absolute rates of 
protein synthesis. Further studies should investigate methods that can accommodate for this 
difference in measurements and modify the protocol as needed. Another limitation to 
SUnSET is the inability to measure puromycin and its effect on the treatment agents. The 
most basic assumption made in this protocol is that the treatment groups do not alter the 
actions of puromycin compared to the basal state i.e. control group. For example, if sAPPα 
induced a change in puromycin uptake, the results would be misrepresenting an increase in 
translation and would be showing an experimentally induced change which is not constant 
across treatment groups. Further studies should look into ways of verifying that treatments 
are not causing any physiological changes to puromycin. Goodman and Hornberger (2013) 
suggested measuring the free pool of puromycin if there is enough tissue to do so which 
could show that the levels are not significantly different across groups.  
 Although the technique of using acute brain slices for in vitro experiments have been 
refined to a point where it is accepted as a valid approach in the field of neuroscience, it still 
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faces some limitations. One major limitation is the survival of the cells once the slice has been 
made. Usually slices from rats can survive for 6-12 hours (Khurana & Li, 2013). Another 
limitation of slice experiments is the lack of input and output found in whole brain experiments. 
healthy cells. Administrating the correct concentration of puromycin and other drugs are a lot 
easier in slice experiments compared to in vivo injections. For this current experiment, slices 
were frozen within 4 hours of slicing increasing the chance of getting 
Another limitation this study is that only protein synthesis was measured. Although 
protein synthesis is necessary for enhanced LTP and its persistence, this study does not 
include any LTP experiments. As mentioned above, there have been studies conducted that 
have investigated both RER and CTα16 peptides in terms of their effects on LTP (Morrissey 
et al., 2019a,b) which support our findings. Therefore, carrying on from the LTP 
experiments, both exogenous full length sAPPα and the peptides of interest investigated in 
this study could be used in hippocampus-dependent memory tasks.  
 No antibody control experiments were run between tubulin and puromycin to show 
they were not cross reacting. However, the tubulin band is very distinct throughout all the 
experiments and do not always line up with the puromycin bands. Therefore, the chance of 
the antibodies cross reacting is low. Visibility and darkness of puromycin bands differed 
between experiments likely due to the Odyssey machine capturing process which can alter 
the exposure levels across experiments. The exposure is always consistent within one blot 
and by using tubulin as a loading control, some bands that look lighter might have a higher 
qualitative value compared to a darker looking lane due to the tubulin reading being lower.  
 
Implications/Applications 
Results from experiment two and three in the present study show evidence to support 
a serial pathway of action between sAPPα and Group 1 mGluR. These results show evidence 
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to support the main hypothesised pathway which states that Group 1 mGluR activation 
stimulates α-secretase to cleave APP into sAPPα resulting in increased protein synthesis. As 
mentioned previously, protein kinase p90rsk is involved in the protein translation complex 
and thought to be one of the ways Group 1 mGluRs can increase protein synthesis. If sAPPα 
is working downstream of Group 1 mGluRs in a serial pathway, it might be acting through 
similar mechanisms to increase protein synthesis. Currently, the exact mechanism of action 
for sAPPα is unknown, this serial pathway could aid in the research towards better 
understanding how sAPPα works. The more that is understood about sAPPα the better a 
potential therapeutic agent will be.  
Neurodegenerative diseases such as AD causes synapses in the brain to breakdown 
therefore causing harmful effects on memory. Due to the plasticity of synapses, the loss of 
function has been shown to be reversible in many cases (Mockett et al., 2017). If there is a 
way to stop, reverse, or even slow down this degenerative process it would be vital to 
investigate. Two ways of seeing the benefits of sAPPα would be to either increase the levels 
of sAPPα by promoting the cleavage of APP by α-secretase or else by administering 
exogenous sAPPα. 
In order to promote the sAPPα pathway, the amyloidogenic pathway would need to be 
suppressed. Previous studies have investigated potential BACE inhibitors (Yan & Vassar, 
2014) and there are several BACE inhibitors in clinical trials (Cumming et al., 2012).  In 
theory the inhibition BACE would increase the α-secretase pathway of APP leading to an 
increase in sAPPα production, however, studies have shown that BACE is not specific to 
APP and therefore the inhibition could lead to complications in normal brain activity (Saftig 
& Lichtenthaler, 2015; Kuhn et al., 2016).  
Another way for more sAPPα to be produced would be to promote the activity of α-
secretase. Studies have investigated potential ways to promote or increase the activity of α-
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secretase with a focus on ADAM10. Acitretin was found to be able to up-regulate ADAM10 
leading to the increase in sAPPα (Tippmann et al., 2009). They found that ADAM10 was 
found to be regulated by retinoic acid which is a bio-reactive metabolite of vitamin A. When 
vitamin A analog acitretin was used, it showed similar effects to retinoic acid and increased 
ADAM10 activity. The use of an ADAM10 inhibiter resulted in acitretin to have no effect 
showing that the vitamin A analog was indeed promoting ADAM10 activity. When testing on 
transgenic mice (APP/PS1-21) intracerebral injection of acitretin resulted in the reduction of 
AB40 and AB42. 
Melatonin is a hormone which is endogenously produced in the brain and its levels 
decrease with age. The rate of reduction is amplified by Alzheimer’s disease. Exogenous 
administration of melatonin has been shown to efficiently decrease levels of Aβ in tg2576 
AD mice (Matsubara et al., 2003). Mechanisms of melatonin’s actions were investigated and 
found to be related to ERK1/2 phosphorylation leading to transcriptional activation of 
ADAM10 increasing sAPPα levels (Shukla et al., 2015). 
Due to the positive effects of sAPPα, there has been a lot of interest for it being used 
as a therapeutic agent to combat AD and other neurodegenerative diseases. sAPPα’s 
neurotropic effects could help prolong a healthy brain; its neuroprotective properties could 
slow down AD in the early onset stage while its neurogenetic characteristics could play a 
central role in repairing damaged synapses.  
As mentioned in the introduction, peptides would be a prime target for a therapeutic 
agent against AD. The peptides investigated have shown promising preliminary results that 
indicate they can mimic the beneficial effects of full length sAPPα in terms of enhancing 
protein synthesis. RER and CTα16 were found to be both required and sufficient to 
significantly increase protein synthesis compared to basal levels in the CA1 hippocampal 
mini-slices. This increase in protein synthesis would likely aid in enhancing and prolonging 
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LTP. Both RER and CTα16 showing positive effects are a good sign for their use as a peptide 
drug to combat neurodegeneration.  
Although both RER and CTα16 peptides have shown promise in producing positive 
effects on protein synthesis, the task of producing these positive effects in the brain is no easy 
feat. As mentioned in the introduction, peptides are more likely to be suitable for an 
administrable drug compared to larger proteins. The mission for a therapeutic agent is to 
cross the blood brain barrier and reach the target organ before being broken down. This 
requires it to be metabolically stable against proteolysis. If RER and CTα16 are going to be 
used as a therapeutic agent, they would need to be modified into a peptide drug. Peptide 
drugs are better equipped to be used as therapeutic agents compared to proteins. Most 
peptides that are turned into peptide drugs undergo chemical modifications that allow them to 
be undetectable by proteolysis, avoiding being cleaved and being broken down (Adessi & 
Soto, 2002). If RER and CTα16 can both be modified and a mechanism of delivery into the 
brain can be achieved it could become an effective peripherally delivered drug to fight 
against AD.  
 
Future Research 
Findings from this paper highlight some clear topics that can be the basis of further 
research. They all mainly serve the purpose to refine the experiments seen here in order to get 
a better understanding of how sAPPα, RER and CTα16 work which will help in the 
progression of a potential therapeutic agent against Alzheimer’s disease.  
Firstly, the concentrations for each treatment agent used in this study were decided 
through previous findings and a few preliminary experiments of our own. However, testing a 
mixture of different concentrations could lead to more optimized results. The concentrations 
could be manipulated to see where the ideal increase in protein synthesis occurs. Other 
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agonists and antagonists could also be substituted for the ones used in this study to see 
whether a more prominent effect is observed.  
Another avenue of further research could investigate the effects of other peptides of 
interest. Both RER and CTα16 were chosen due to previous studies showing vast amounts of 
potential in their ability to mimic sAPPα. Other peptides related to APP could be tested to see 
if they can promote protein synthesis. Two peptides derived from APP; NWC15 
(NWCKRGRKQCKTHPH) and NWC20c (NWCKRGRKQCKTHPHFVIPY) were found to 
be important molecules in the innate immune system and could be a target for further 
research (Papareddy et al., 2012).  
As mentioned, one of the main implications that results from this study could have is 
in the development of a peptide drug based therapeutic agent against AD. For this to occur, 
further research needs to be done on the two peptides investigated. One vital aspect of these 
peptides is how similar they are to the parent molecule sAPPα in terms of being able to 
enhance protein synthesis. In this present study we have shown that both RER and CTα16 
can increase protein synthesis, but it would also be interesting to further investigate both RER 
and CTα16 to see if they can produce any other effects of sAPPα. This could be tested by 
using the two peptides in place of sAPPα in previously completed experiments such as 
memory tasks and memory rescue in APP/PS1 mice (Mockett et al., 2017). 
Another aspect that should be investigated for the peptides are the novel effects they 
might have. Although this study has shown both RER and CTα16 to act in a very similar 
manner to sAPPα in terms of increasing protein synthesis, due to them only being peptide 
fragments of the parent molecule there could be unexpected results with increased amounts of 
investigation. It will be vital for these peptides to be put through further experiments in order 
to get a better understanding of their actions. An important part to look at would be to test 
whether these peptides are inhibiting any aspect of healthy brain function (Baratachi et al., 
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2012). The specificity of both peptides would need to be investigated. Both have shown great 
potential in the CA1 of the hippocampus but being used as a peptide drug requires them to 
not interfere with normal brain activity. Brain activity could be tested through the use of an 
fMRI.  
Finally, for RER and CTα16 to be used as a therapeutic agent, they need to be 
modified into peptide drugs. Morrissey et al. (2019b) modified the CTα16 into two stable 
peptides more suitable for drug therapy. Following literature on how to stabilize peptides, 
they produced two modified versions of CTα16.  Firstly, the CTα16 peptide was modified by 
adding a t-BUCOHN cap at the N-terminus and the carboxyl group at the C-terminus was 
replaced with an amino group. The second peptide was modified by changing the chirality of 
the fifth amino acid (arginine) from L- to D- orientation. Both these modifications were done 
in order to reduce recognition by endopeptidases. Their study investigated the effects these 
modified peptides had on in vitro LTP. They found that neither modified peptide was able to 
significantly increase LTP levels at induction however, Bn-CTα16-NH2 was able to 
significantly increase LTP measured 55- 60 minutes post theta burst stimulation.  
Mileusnic et al. (2007) modified the RER peptide into a more stable form by changing 
the first amino acid (arginine) in the peptide chain from L- to D- orientation. Their study 
showed that the modified version was able to rescue Aβ induced memory loss and in a 
passive avoidance task in new born chicks. They stated that this modified version easily 
crosses the blood brain barrier and minds to receptor sites without any adverse effects on 
normal behaviour. 
Although the above examples show modified more stable versions of the peptides 
investigated, they are not in human trials and therefore it is uncertain if they will be stable in 
human physiology. As mentioned before, human therapeutic agents need to be able to cross 
the blood-brain barrier. Modified peptides should be tested for their blood-brain penetration 
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capability to ensure they are reaching intended target. NeuroCart is a relatively new protocol 
that can test time and dose dependent effects of a compound and therefore could be used to 
test batches of peptides before clinical trials (Groeneveld et al., 2016). 
Conclusion 
Results from this study showed sAPPα being able to increase protein synthesis 
displayed through the SUnSET protocol. The use of multiple drugs has shown evidence for a 
serial pathway of action in which Group 1 mGluRs are acting upstream of α-secretase. This 
proposed interaction between α-secretase and Group 1 mGluR could help in better 
understanding the mechanisms of sAPPα and its beneficial effects. RER and CTα16 were 
shown to be able to mimic full length sAPPα in the enhancement of protein synthesis. Both 
peptides investigated were not only required but sufficient in isolation to promote protein 
synthesis. Through refinement, these findings could hopefully play a part in the research 
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10x running buffer: 25 mM Tris/192 nM glycine/0.1% SDS 
30g of Tris + 144 g glycine + 10 g SDS adjust to final volume of 1 L with MQ.  
Lower gel buffer 4x: 1.5 M Tris-Cl/pH 8.8/0.4% SDS 
72.66 g Tris + MQ up to 350 ml. Adjust pH to 8.8 using HCl. Then add 1.6 g SDS and adjust 
to final volume of 400 ml with MQ.  
Upper gel buffer 4x: 0.5 M Tris-Cl/pH 6.8/0.4% SDS 
24.22 g Tris in 300 ml of MQ. Adjust pH to 6.8 using HCl. Then add 1.6 g of SDS and adjust 
to final volume of 400 ml with MQ. 
Sample buffer 10x: 0.625 M Tris-Cl/pH 6.8/10% SDS 
7.5 g Tris in 80 ml MQ. Adjust pH to 6.8 using HCl. Then add 10 g of SDS and adjust to 
final volume of 100 ml with MQ.  
NOVEX solution 25x: 25 mM Tris/192 nM glycine 
36.25 g of Tris + 180 g glycine and adjust to final volume of 1 L with MQ.  
PBS/PBS with Tween 
5.92 g H2NaO4P (80 mM) 
23 g NaH2PO4 · 2H2O (20 mM) 
11.68 g NaCl (100 mM) 
Make up to 2 L using MQ. For tween add 2 ml tween (0.1%).  
 
 
